Researches on fibronectin mainly focused on its application as a target for precise drug delivery, several therapies as targeting fibronectin EDA and extra domain B (EDB) have been developed in an attempt to inhibit tumor neovasculature (Castellani et al., 1994). This evidence concerns the gene FN1 and neoplasm.